NASDAQ:CNTA Centessa Pharmaceuticals (CNTA) Stock Price, News & Analysis $15.51 -0.43 (-2.70%) (As of 10/7/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Centessa Pharmaceuticals Stock (NASDAQ:CNTA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CNTA alerts:Sign Up Key Stats Today's Range$15.46▼$15.9750-Day Range$10.07▼$17.2052-Week Range$5.58▼$17.59Volume197,603 shsAverage Volume402,449 shsMarket Capitalization$1.56 billionP/E RatioN/ADividend YieldN/APrice Target$25.17Consensus RatingBuy Company OverviewCentessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.Read More… Notice: Major payout due November 19th - are you on the list? (Ad)On Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's part of a unique strategy which has nothing to do with risky investments like options, cryptos or forex. And while it might sound crazy...Click here for the ticker >>> Centessa Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks86th Percentile Overall ScoreCNTA MarketRank™: Centessa Pharmaceuticals scored higher than 86% of companies evaluated by MarketBeat, and ranked 154th out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingCentessa Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCentessa Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Centessa Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Centessa Pharmaceuticals are expected to decrease in the coming year, from ($1.62) to ($1.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Centessa Pharmaceuticals is -10.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Centessa Pharmaceuticals is -10.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCentessa Pharmaceuticals has a P/B Ratio of 6.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Centessa Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.99% of the float of Centessa Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCentessa Pharmaceuticals has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Centessa Pharmaceuticals has recently decreased by 23.86%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCentessa Pharmaceuticals does not currently pay a dividend.Dividend GrowthCentessa Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.99% of the float of Centessa Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCentessa Pharmaceuticals has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Centessa Pharmaceuticals has recently decreased by 23.86%, indicating that investor sentiment is improving significantly. News and Social Media3.9 / 5News Sentiment1.04 News SentimentCentessa Pharmaceuticals has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Centessa Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest2 people have searched for CNTA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows7 people have added Centessa Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Centessa Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,641,902.00 in company stock.Percentage Held by Insiders11.59% of the stock of Centessa Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.01% of the stock of Centessa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Centessa Pharmaceuticals' insider trading history. Receive CNTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Centessa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CNTA Stock News HeadlinesWake Up to This Biotech Stock That Still Has Big Potential UpsideCentessa Pharmaceuticals released strong results in Phase 1 trials and now Wall Street analysts are buzzing over the stock.September 28, 2024 | marketbeat.comGregory M. Weinhoff Sells 16,619 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) StockSeptember 28, 2024 | insidertrades.comWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.October 8, 2024 | Porter & Company (Ad)Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha Sells 55,000 SharesSeptember 21, 2024 | insidertrades.comSaurabh Saha Sells 175,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) StockSeptember 13, 2024 | insidertrades.comCentessa Pharmaceuticals (NASDAQ:CNTA) Shares Down 3.3% - What's Next?October 4, 2024 | americanbankingnews.comCentessa Pharmaceuticals (NASDAQ:CNTA) Stock Price Up 6.2% - Here's WhyOctober 3, 2024 | americanbankingnews.comCentessa Pharmaceuticals’ ORX142 Shows Promising Preclinical Results and Market PotentialSeptember 27, 2024 | markets.businessinsider.comSee More Headlines CNTA Stock Analysis - Frequently Asked Questions How have CNTA shares performed this year? Centessa Pharmaceuticals' stock was trading at $7.96 at the beginning of 2024. Since then, CNTA shares have increased by 94.8% and is now trading at $15.51. View the best growth stocks for 2024 here. How were Centessa Pharmaceuticals' earnings last quarter? Centessa Pharmaceuticals plc (NASDAQ:CNTA) announced its earnings results on Tuesday, August, 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by $0.02. When did Centessa Pharmaceuticals IPO? Centessa Pharmaceuticals (CNTA) raised $285 million in an IPO on Friday, May 28th 2021. The company issued 15,000,000 shares at $18.00-$20.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Jefferies and Evercore ISI were co-managers. Who are Centessa Pharmaceuticals' major shareholders? Top institutional investors of Centessa Pharmaceuticals include GAMMA Investing LLC. Insiders that own company stock include Antoine Yver, Saurabh Saha, David M Chao, Gregory M Weinhoff, Tia L Bush, Iqbal J Hussain, Thomas Templeman, Harris Rotman, Medicxi Ventures Management (J, David J Grainger, Rubertis Francesco De and Aaron Kantoff. View institutional ownership trends. How do I buy shares of Centessa Pharmaceuticals? Shares of CNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/13/2024Today10/08/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CNTA CUSIPN/A CIK1847903 Webwww.centessa.com Phone44-73-9178-9784FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Stock Price Target$25.17 High Stock Price Target$35.00 Low Stock Price Target$14.00 Potential Upside/Downside+62.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-151,090,000.00 Net MarginsN/A Pretax Margin-2,303.27% Return on Equity-63.08% Return on Assets-42.97% Debt Debt-to-Equity Ratio0.27 Current Ratio13.29 Quick Ratio13.29 Sales & Book Value Annual Sales$6.85 million Price / Sales227.42 Cash FlowN/A Price / Cash FlowN/A Book Value$2.42 per share Price / Book6.41Miscellaneous Outstanding Shares100,482,000Free Float88,836,000Market Cap$1.56 billion OptionableOptionable Beta1.46 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report This page (NASDAQ:CNTA) was last updated on 10/8/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredU.S. Stock Market Now on Verge of Collapse"Wheels Are Falling Off" The U.S. Stock Market Today, analyst Dan Ferris is back issuing a new warning. He ...Stansberry Research | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored320 hedge funds just sold this stock320 hedge funds just sold this stock A strange force has seized control of Wall Street. Hedge funds are alr...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Centessa Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Centessa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.